What are the steps for testosterone testing and treatment?

Steps for Testosterone Testing and Treatment

Follow the Endocrine Society's 2010 systematic approach: confirm biochemical hypogonadism with two morning testosterone measurements, assess for clinical symptoms, exclude contraindications, initiate appropriate formulation, and monitor at 3-6 months then annually for efficacy and safety parameters including testosterone levels, hematocrit, and prostate surveillance in men ≥40 years. 1

Initial Diagnostic Testing

Biochemical Confirmation

• Obtain two separate morning fasting testosterone measurements to confirm low testosterone
• Target threshold: Total testosterone <350 ng/dL (12.1 nmol/L) or free testosterone <65-100 pg/mL warrants consideration for therapy 2
• **Morning testing is mandatory for men <40 years**; men >40 years may have initial afternoon testing but require confirmatory morning samples 2
• Recognize that sex hormone binding globulin variability affects total testosterone interpretation—free testosterone correlates more closely with symptoms 2

Baseline Safety Assessments

Before initiating therapy, obtain:

• Hematocrit: Baseline >50% is a relative contraindication (many will exceed 54% on therapy and require discontinuation) 1
• PSA and digital rectal examination in men ≥40 years with baseline PSA >0.6 ng/mL 1
• Evaluate for sleep apnea and hypoxia if present 1
• Screen for prostate abnormalities and lower urinary tract symptoms

Critical pitfall: Men with hematocrit >50% require clinical evaluation before therapy—do not proceed without addressing underlying causes of polycythemia 1

Treatment Initiation

Formulation Selection and Dosing

The goal is to achieve mid-normal range testosterone levels for healthy young men 1, 3. Formulation-specific monitoring timing varies:

Injectable testosterone (enanthate/cypionate):

• Measure testosterone midway between injections
• Adjust if levels are >700 ng/dL or <400 ng/dL 1

Transdermal gels:

• Assess testosterone anytime after ≥1 week of treatment
• Measure 2-8 hours after application 3
• Warn patients: Cover application sites with clothing and wash skin before skin-to-skin contact to prevent transfer to women/children 1

Transdermal patches:

• Check levels 3-12 hours after application 1

Buccal tablets:

• Assess immediately before or after fresh system application 1

Injectable testosterone undecanoate:

• Measure just prior to subsequent injection 1

Monitoring Protocol

Initial Follow-up (3-6 months)

Mandatory assessments 1, 3:

1. Testosterone level: Confirm achievement of mid-normal range using formulation-specific timing
2. Hematocrit: If >54%, stop therapy immediately until it decreases; evaluate for hypoxia/sleep apnea; restart at reduced dose 1
3. Symptom response: Assess sexual function, energy, mood
4. PSA and digital rectal examination (men ≥40 years with baseline PSA >0.6 ng/mL) 1

Annual Monitoring

Continue checking 1:

• Testosterone levels (adjust dose to maintain mid-normal range)
• Hematocrit annually
• PSA and digital rectal examination per age-appropriate screening guidelines
• Formulation-specific adverse effects

Specialized Monitoring

Bone density: Measure lumbar spine/femoral neck after 1-2 years in men with osteoporosis or low-trauma fracture 1

Prostate surveillance triggers for urological referral 1, 3:

• PSA increase >1.4 ng/mL within any 12-month period
• PSA velocity >0.4 ng/mL/year (using 6-month level as reference, applicable if >2 years data)
• Confirmed PSA >4.0 ng/mL
• Prostatic abnormality on digital rectal examination
• AUA/IPSS symptom score >19

Critical distinction: Men <40 years have very low prostate cancer risk and may not require prostate monitoring 1

Key Safety Considerations

Absolute Monitoring Requirements

The hematocrit threshold of 54% is non-negotiable—therapy must be stopped at this level 1. This is the most common serious adverse effect requiring intervention.

Formulation-Specific Adverse Effects

Assess at each visit 1:

• Buccal tablets: Taste alterations, gum/oral mucosa irritation
• Injectable esters: Mood/libido fluctuations, rare cough after injection
• Patches: Skin reactions at application site
• Gels: Risk of transfer (counsel on covering/washing)

Special Populations

Older men without classical hypogonadism: The evidence for benefit is limited and inconsistent. Consider individualized 6-month empirical trials only in symptomatic men with strongly suggestive symptoms, after explicit discussion of uncertain risk-benefit profile 4

Men with type 2 diabetes: Follow the same treatment and monitoring protocol as other hypogonadal men 3

Common Pitfalls to Avoid

1. Single testosterone measurement: Always confirm with two separate measurements before diagnosis
2. Ignoring morning timing: Non-morning samples in younger men lead to misdiagnosis
3. Inadequate baseline hematocrit screening: Missing elevated baseline hematocrit leads to dangerous polycythemia
4. Insufficient prostate surveillance: Missing the age-specific PSA thresholds (>0.6 ng/mL at age 40) that trigger monitoring requirements
5. Treating asymptomatic men: Biochemical low testosterone alone without symptoms is not an indication for therapy 4